Zura Bio Limited (NASDAQ:ZURA) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Zura Bio Limited (NASDAQ:ZURA) have been given a consensus recommendation of “Buy” by the six research firms that are presently covering the firm, Marketbeat reports. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $18.00.

Several research analysts have commented on ZURA shares. Oppenheimer reissued an “outperform” rating and set a $16.00 target price (down previously from $17.00) on shares of Zura Bio in a research note on Monday, April 1st. Piper Sandler initiated coverage on shares of Zura Bio in a research note on Friday, May 3rd. They issued an “overweight” rating and a $26.00 price objective for the company.

Insiders Place Their Bets

In other Zura Bio news, Director Amit Munshi purchased 159,744 shares of the business’s stock in a transaction dated Monday, April 22nd. The shares were bought at an average price of $3.13 per share, for a total transaction of $499,998.72. Following the completion of the acquisition, the director now owns 777,384 shares in the company, valued at $2,433,211.92. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have acquired 170,926 shares of company stock valued at $534,998 in the last ninety days. 15.80% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Zura Bio

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Lynx1 Capital Management LP bought a new position in Zura Bio during the 3rd quarter worth approximately $65,000. Forefront Analytics LLC acquired a new stake in Zura Bio during the 3rd quarter worth about $95,000. Bank of New York Mellon Corp bought a new position in shares of Zura Bio in the 3rd quarter worth about $224,000. Raymond James & Associates raised its position in shares of Zura Bio by 14.0% in the 3rd quarter. Raymond James & Associates now owns 77,356 shares of the company’s stock worth $511,000 after acquiring an additional 9,481 shares in the last quarter. Finally, Eisler Capital US LLC acquired a new position in shares of Zura Bio in the 3rd quarter valued at about $660,000. Institutional investors and hedge funds own 61.14% of the company’s stock.

Zura Bio Stock Down 1.1 %

Shares of ZURA stock opened at $4.64 on Friday. Zura Bio has a fifty-two week low of $2.00 and a fifty-two week high of $14.00. The stock’s fifty day moving average price is $3.30 and its two-hundred day moving average price is $3.92.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.